Effect of duration of diabetes mellitus on the prevalence of diabetic retinopathy in patients with type 2 diabetes and metabolic syndrome
https://doi.org/10.14341/2072-0351-5682
Abstract
Aim.
To study effect of duration of diabetes mellitus on the prevalence of diabetic retinopathy (DR) in patients with type 2 diabetes (DM2) andmetabolic syndrome (MS) or without it.
Materials and methods.
The study included 115 patients with type 2 diabetes and metabolic syndrome and 45 patients with DM2 without MS (controls).Of 115 MS patients and of 45 control ones, 42 and 17 respectively presented with different forms of DR. Ophthalmological examination was performedby generally accepted methods including visiometry, tonometry, biomicroscopy, ophthalmoscopy, and fluorescent angiography.
Results.
The study revealed a well-apparent tendency toward an increase of DR occurrence in MS patients with duration of DM2 (10.0%, 53.1%,82.6% during 0-4, 5-9, and 10 or more years respectively). Significant difference between DR incidence was recorded in MS patients having DM2for 0-4 and 5-9 years (p<0.001, FET). Similar difference was documented in MS patients with the duration of DM2 5-9 and 10 or more years(p<0.01, FET). Analogous tendency was observed in control group (20.8%, 53.8% and 62.5%). The difference between DR incidence in control patientswith DM2 0-4 and 5-9 years in duration was statistically significant (p<0.01, FET) unlike the difference between DR incidence in DM2 of 5-9 and over 10 years (p >0.05, FET). Correlation between occurrence of DR and HbA1c levels failed to reach statistical significance (r bs = 0.023,p>0.05 in MS patients and r bs = 0.064, p>0.05 in controls).
Conclusion.
Occurrence of DR increases with duration of DM2 with and without MS but fails to correlate with HbA1c levels in either condition.
To study effect of duration of diabetes mellitus on the prevalence of diabetic retinopathy (DR) in patients with type 2 diabetes (DM2) andmetabolic syndrome (MS) or without it.
Materials and methods.
The study included 115 patients with type 2 diabetes and metabolic syndrome and 45 patients with DM2 without MS (controls).Of 115 MS patients and of 45 control ones, 42 and 17 respectively presented with different forms of DR. Ophthalmological examination was performedby generally accepted methods including visiometry, tonometry, biomicroscopy, ophthalmoscopy, and fluorescent angiography.
Results.
The study revealed a well-apparent tendency toward an increase of DR occurrence in MS patients with duration of DM2 (10.0%, 53.1%,82.6% during 0-4, 5-9, and 10 or more years respectively). Significant difference between DR incidence was recorded in MS patients having DM2for 0-4 and 5-9 years (p<0.001, FET). Similar difference was documented in MS patients with the duration of DM2 5-9 and 10 or more years(p<0.01, FET). Analogous tendency was observed in control group (20.8%, 53.8% and 62.5%). The difference between DR incidence in control patientswith DM2 0-4 and 5-9 years in duration was statistically significant (p<0.01, FET) unlike the difference between DR incidence in DM2 of 5-9 and over 10 years (p >0.05, FET). Correlation between occurrence of DR and HbA1c levels failed to reach statistical significance (r bs = 0.023,p>0.05 in MS patients and r bs = 0.064, p>0.05 in controls).
Conclusion.
Occurrence of DR increases with duration of DM2 with and without MS but fails to correlate with HbA1c levels in either condition.
About the Authors
Rena kyzy Guseynova
Centre of Endocrinology, Diabetes and Metabolism, Baku
Valekh ogly Mirzazadze
Centre of Endocrinology, Diabetes and Metabolism, Baku
References
1. Клинические рекомендации. Офтальмология / Под ред. Л.К Мошетовой, А.П. Нестерова, Е.А. Егорова - М.: ГЭОТАР- Медиа, 2006.
2. Балаболкин М.И. Диабетология. М.: Медицина, 2000. 671 c.
3. Шевченко О.П., Праскурничий Е.А., Шевченко А.О. - Метаболический синдром. - М.: Реафарм, 2004. - 141 с.
4. Klein R., Klein B.E., Moss S.E., Davis M.D., DeMets D.L. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II Prevalence and risk factor of diabetic retinopathy when age at diagnisis is less than 30 years // Arch. Ophthalmol. - 1984. - Vol. 102. - Р. 520-526.
5. Kohner E.M.S., Porta M. creening for diabetic retinopathy in Europe: a fild guide - London, 1992. - 51 p.
6. Huseynova R.R., Mirzazada V.A., Kerimov K.T. Development of diabetic retinopathy in metabolic syndrome. Influence of and duration of diabetes // Azerbaijan Journal of Metabolizm. - 2008. - Vol. 10, № 1. - P. 12-15.
7. Лакин Г.Ф. Биометрия. М.: Высшая школа, 1980. - 293 с.
8. Гублер Е.В. Вычислительные методы анализа и распознавания патологических процессов. - М.: Медицина, 1978. - 296 с.
9. Varma R., Torres M., Peсa F., Klein R., Azen S.P. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study // Ophthalmology. - 2004. - Vol. 111, № 7. - Р. 1298-1306.
10. Wang F., Liang Y., Zhang F., Wang J., Wei W., Tao Q., Sun L., Friedman D., Wang N., Wong T. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study // Ophthalmology. - 2009. - Vol. 116, № 3. - P. 461-467.
11. Chetthakul T., Deerochanawong C., Suwanwalaikorn S., Kosachunhanun N., Ngarmukos C., Rawdaree P., Krittiyawong S., Leelawatana R., Bunnag P., Plengvidhya N., Pratipanawatr T., Benjasuratwong Y., Mongkolsomlit S. Thailand diabetes registry project: prevalence of diabetic retinopathy and associated factors in type 2 diabetes mellitus // J. Med. Assoc. Thai. - 2006. - Suppl. 1. - Р. 27-36.
12. Raman R., Rani P., Reddi Rachepalle S., Gnanamoorthy P., Uthra S., Kumaramanickavel G., Sharma T. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2 // Ophthalmology. - 2009. - Vol. 116, № 2. - P. 311-318.
Review
For citations:
Guseynova R.k., Mirzazadze V.o. Effect of duration of diabetes mellitus on the prevalence of diabetic retinopathy in patients with type 2 diabetes and metabolic syndrome. Diabetes mellitus. 2010;13(2):94-96. (In Russ.) https://doi.org/10.14341/2072-0351-5682
Views:
442
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
